Michael Ciliberto, MD
Epilepsy · Iowa City, IANPI 1043418809
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Zogenix Inc. at 50.5% of the total.
Across 5 payments — averaging $554.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zogenix Inc.$1K
- H. Lundbeck A S$1K
- Takeda Pharmaceuticals U.S.A., Inc.$61
Across 120 payments — averaging $5040.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$450K
- GW Research Limited$110K
- H. Lundbeck A S$34K
- Immedica Pharma US, Inc.$11K
What the payments were for
- Consulting fees$1,40051%
- Travel & lodging$1,31147%
- Food & beverage$612%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zogenix Inc. | 1 | $1,400 |
| H. Lundbeck A S | 3 | $1,311 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$1,400
How this compares
Too few epilepsy providers in Iowato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 44 | $54,272 |
| Rufinamide | 30 | $44,619 |
| EpidiolexCannabidiol (Cbd) | 18 | $29,608 |
| Clobazam | 62 | $11,165 |
| Lacosamide | 32 | $1,333 |
| Valproic AcidValproic Acid (As Sodium Salt) | 28 | $1,330 |
| Divalproex Sodium ErDivalproex Sodium | 18 | $964 |
| Oxcarbazepine | 11 | $831 |
| Levetiracetam | 40 | $695 |
| Topiramate | 24 | $636 |
| Levocarnitine | 13 | $623 |
| Gabapentin | 13 | $501 |
| Phenobarbital | 13 | $411 |
| Clonazepam | 14 | $262 |
| Divalproex Sodium | 24 | $216 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Iowa City
- James OwensIowa City$2K
- Anna DabrowskiIowa City$522
- Brittany SpriggIowa City$332
- Gena GhearingIowa City$142
- Theresa CzechIowa City$121
- Tuhina Govil-DalelaIowa City$111
- Sreenath Thati GangannaIowa City$14
- Aradia FuDes Moines$217
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.